How the Incretin Hormones GIP and GLP-1 Together Protect Against Diabetes, Obesity, and Heart Disease
Dual GIP/GLP-1 agonists like tirzepatide outperform single GLP-1 drugs for blood sugar control and weight loss, while both incretins offer significant cardiovascular protection.
Quick Facts
What This Study Found
Dual GIP/GLP-1 receptor agonists, led by tirzepatide, provide superior glycemic control and weight loss compared to selective GLP-1 receptor agonists alone, demonstrating synergistic effects between the two incretin pathways. GIP, historically overlooked due to reduced beta-cell responsiveness in type 2 diabetes, has been rehabilitated as a therapeutic target through dual agonism.
The review identifies multiple cardiovascular protective mechanisms of incretin hormones: improved lipid metabolism, blood pressure reduction, enhanced endothelial nitric oxide activity, suppressed macrophage inflammation, decreased foam-cell formation, and atherosclerotic plaque stabilization. Emerging triple agonists and genotype-guided incretin therapy represent the next frontier.
Key Numbers
2 incretin hormones (GIP + GLP-1) · Tirzepatide first-in-class dual agonist · Superior to selective GLP-1RAs · Multiple CV protective mechanisms · Triple agonists in development
How They Did This
Comprehensive narrative review covering incretin biology from basic physiology through clinical therapeutics. Synthesizes evidence on secretion patterns, receptor distributions, pathophysiology in diabetes and obesity, cardiovascular mechanisms, and emerging therapeutic approaches.
Why This Research Matters
The shift from single GLP-1 agonists to dual and triple incretin agonists represents a paradigm change in metabolic medicine. Understanding how GIP and GLP-1 work together — not just for blood sugar and weight, but also for cardiovascular protection — reshapes how we think about treating the interconnected diseases of diabetes, obesity, and heart disease as a unified metabolic syndrome.
The Bigger Picture
The incretin field has evolved from simple blood sugar management to comprehensive metabolic and cardiovascular therapy. The recognition that GIP — once dismissed as ineffective in diabetes — contributes powerfully when combined with GLP-1 agonism has opened entirely new therapeutic strategies. This integrated approach to treating metabolic disease may fundamentally change how physicians manage the overlapping conditions of diabetes, obesity, and cardiovascular disease.
What This Study Doesn't Tell Us
As a narrative review, this does not provide systematic evidence grading or pooled analysis. Long-term cardiovascular effects of GIP specifically remain unresolved. The review acknowledges that genotype-guided incretin therapy is still speculative.
Questions This Raises
- ?What are the long-term cardiovascular effects of GIP agonism specifically, independent of GLP-1?
- ?Could genotype-guided selection of incretin therapies improve individual patient outcomes?
- ?How will triple agonists (targeting GLP-1, GIP, and glucagon receptors) compare to dual agonists in efficacy and safety?
Trust & Context
- Key Stat:
- Dual agonists outperform single GLP-1 drugs Tirzepatide, the first dual GIP/GLP-1 agonist, shows superior glycemic control and weight loss compared to selective GLP-1 receptor agonists in clinical trials
- Evidence Grade:
- This is a comprehensive narrative review synthesizing evidence from basic science through clinical trials. The underlying evidence for GLP-1 agonists and tirzepatide comes from large randomized controlled trials, providing strong clinical evidence.
- Study Age:
- Published in 2025, this review captures the very latest developments including tirzepatide's clinical success and emerging triple agonist approaches.
- Original Title:
- The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.
- Published In:
- International journal of molecular sciences, 27(1) (2025)
- Authors:
- Yamanouchi, Dai
- Database ID:
- RPEP-14304
Evidence Hierarchy
Frequently Asked Questions
What are incretin hormones and what do they do?
Incretins are hormones released by the gut after eating. The two main incretins — GIP and GLP-1 — stimulate insulin release, reduce appetite, slow stomach emptying, and protect the cardiovascular system. Drugs that mimic these hormones have become transformative treatments for diabetes and obesity.
Why is tirzepatide considered a breakthrough compared to earlier GLP-1 drugs?
Tirzepatide activates both the GIP and GLP-1 receptors simultaneously, producing greater blood sugar improvement and weight loss than drugs targeting GLP-1 alone. This dual mechanism captures synergistic benefits from both incretin pathways, representing a new class of metabolic therapy.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14304APA
Yamanouchi, Dai. (2025). The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.. International journal of molecular sciences, 27(1). https://doi.org/10.3390/ijms27010027
MLA
Yamanouchi, Dai. "The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.." International journal of molecular sciences, 2025. https://doi.org/10.3390/ijms27010027
RethinkPeptides
RethinkPeptides Research Database. "The Roles of Incretin Hormones GIP and GLP-1 in Metabolic an..." RPEP-14304. Retrieved from https://rethinkpeptides.com/research/yamanouchi-2025-the-roles-of-incretin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.